Filing Flows › Comparisons › PBLS vs HCWB
Parabilis Medicines vs HCW Biologics: PBLS and HCWB compared
Parabilis Medicines is the larger company: $148K of revenue in its latest quarter (Q2 2026) against $136K for HCW Biologics (Q2 2026).
Where the money goes: PBLS and HCWB
Parabilis Medicines (PBLS) · Q2 2026
Parabilis Medicines, Q2 2026: revenue $148K, net loss $52.5M. The chart follows the revenue to costs, profit and cash.
HCW Biologics (HCWB) · Q2 2026
HCW Biologics, Q2 2026: revenue $136K (21× year over year), net loss $5.2M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Parabilis Medicines (PBLS) | HCW Biologics (HCWB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $148K | $136K |
| Revenue growth, Y/Y | — | 21× |
| Operating margin | n/m | n/m |
| Net earnings | −$52.5M | −$5.2M |
| Operating cash flow | — | −$4.0M |
Questions
Which is bigger, Parabilis Medicines or HCW Biologics?
Parabilis Medicines is the larger company: $148K of revenue in its latest quarter (Q2 2026) against $136K for HCW Biologics (Q2 2026).
More: Parabilis Medicines earnings · how Parabilis Medicines makes money · HCW Biologics earnings · how HCW Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.